CARMAT says its Aeson artificial heart product will form part of French
clinical study
Send a link to a friend
[January 04, 2023]
PARIS (Reuters) - French healthcare and medical technology
company CARMAT said on Wednesday that its Aeson artificial heart product
would be implemented within the framework of a clinical study in France
known as 'EFICAS'.
"EFICAS is the largest study undertaken by CARMAT at this stage, and I
am delighted that it will entirely take place in France, thus enabling
our country's patients to benefit from our therapy. This is a crucial
study, as it will eventually notably allow us to obtain Aeson’s
reimbursement in France," said CARMAT chief executive Stéphane Piat in a
statement.
[to top of second column]
|
![](../images/010423PIX/health65.jpg)
Chief Executive Officer of French
artificial heart manufacturer Carmat, Stephane Piat, poses holding
an artificial heart during an interview with Reuters in Velizy, near
Paris, January 11, 2021. REUTERS/Christian Hartmann TPX IMAGES OF
THE DAY
![](http://archives.lincolndailynews.com/2023/Jan/04/images/ads/current/culligan_sda_FROMCLASSIFIED_122922.png) (Reporting by Sudip Kar-Gupta;
Editing by Christopher Cushing)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |